Divergent Synthesis of scyllo-Inositol Aldoxime Derivatives as Potential Inhibitors of Amyloid-Beta(1-42) Aggregate Formation
scyllo-Inositol is currently in phase II clinical trials as a therapeutic for Alzheimer’s disease (AD). Previous work from our lab has shown that scyllo-inositol prevents Ab1-42 fibril formation instead leading to the formation of small Ab oligomers in vitro. To further understand the molecular deta...
| Main Author: | |
|---|---|
| Other Authors: | |
| Language: | en_ca |
| Published: |
2010
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/1807/24951 |